

COPY

University of Colorado
Medical Center
4200 East Ninth Avenue
Denver 7, Colorado

March 28, 1955

Mr. Manfred Bowditch
Director of Health and Safety
Lead Industries Association
420 Lexington Avenue
New York 17, N. Y.

Dear Mr. Bowditch:

At the present time we are in agreement with Dr. Johnstone and Dr. Kehoe with regard to the prophylactic use of Ca EDTA.

For your information we have been studying the total 24-hr. excretion of lead after treatment with intravenous as well as oral Ca EDTA. Our findings in humans do not agree with the findings of Reider on animals at the University of Pennsylvania, in that we have found the total excretion has been increased with oral Ca EDTA.

Dr. Karr of Riker Laboratories recently had the opportunity of seeing these results and just last week the Riker Laboratories gave us a small grant to continue these studies.

We hope this clarifies our position in this debatable question at the present time with you, and wish to send you our best personal regards.

Sincerely yours,

RFB:kk

Robert F. Bell, M.D.
Acting Head
Division of Industrial Medicine

KE 0008626

N9770